Rajan Dewar

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
    Rajan Dewar
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
    Cancer Biol Ther 11:552-8. 2011
  2. ncbi request reprint Hinduism and death with dignity: historic and contemporary case examples
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, YA 309, Boston, Massachusetts 02215 USA
    J Clin Ethics 26:40-7. 2015
  3. doi request reprint Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Arch Pathol Lab Med 135:422-9. 2011
  4. pmc Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells
    Octavian Bucur
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America Institute of Biochemistry of the Romanian Academy, Bucharest, Romania
    PLoS ONE 8:e77390. 2013
  5. doi request reprint "Apologies" from pathologists: why, when, and how to say "sorry" after committing a medical error
    Rajan Dewar
    1Beth Israel Deaconess Medical Center, Boston, MA, USA
    Int J Surg Pathol 22:242-6. 2014

Collaborators

  • Allen M Gown
  • Oluwole Fadare
  • Octavian Bucur
  • Bodvael Pennarun
  • Andreea Lucia Stancu
  • Stefana Maria Petrescu
  • Roya Khosravi-Far
  • Thierry Bertomeu
  • Ioana Goganau

Detail Information

Publications5

  1. pmc Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
    Rajan Dewar
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
    Cancer Biol Ther 11:552-8. 2011
    ..Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated...
  2. ncbi request reprint Hinduism and death with dignity: historic and contemporary case examples
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, YA 309, Boston, Massachusetts 02215 USA
    J Clin Ethics 26:40-7. 2015
    ..Through an awareness of some of the fundamental practices in Hinduism and the role of individual interpretation within the tradition, clinicians will be better able to support their Hindu patients and families at the end of life. ..
  3. doi request reprint Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Arch Pathol Lab Med 135:422-9. 2011
    ....
  4. pmc Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells
    Octavian Bucur
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America Institute of Biochemistry of the Romanian Academy, Bucharest, Romania
    PLoS ONE 8:e77390. 2013
    ..These results open novel possibilities for the treatment of Bcr-Abl-positive leukemias, especially in the imatinib, dasatinib and nilotinib-resistant CML cases...
  5. doi request reprint "Apologies" from pathologists: why, when, and how to say "sorry" after committing a medical error
    Rajan Dewar
    1Beth Israel Deaconess Medical Center, Boston, MA, USA
    Int J Surg Pathol 22:242-6. 2014
    ..Such interactions promote healing for the patient and are relieving to the well-intentioned pathologist...